The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% – Yahoo Finance

during the forecast period. Growth in this market is majorly driven by the increasing investment in stem cell research and the rising number of GMP-certified stem cell manufacturing plants. However, factors such as ethical concerns and the high cost of stem cell research and manufacturing process likely to hinder the growth of this market.

New York, May 06, 2021 (GLOBE NEWSWIRE) -- announces the release of the report "Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2026" -

The allogeneic stem cell therapy segment accounted for the highest growth rate in the stem cell therapy market, bytype, during the forecast periodThe stem cell therapy market is segmented intoallogeneic and autologous stem cell therapy.Allogeneic stem therapy segment accounted for the largest share of the stem cell therapy market.

The large share of this segment can be attributed to the lesser complexities involved in manufacturing Alaogeneic-based therapies. This segment is also expected to grow at the highest growth rate due to the increasing number of clinical trials in manufacturing allogeneic-based products.

Bone Marrow-derived MSCssegment accounted for the highest CAGR

Based on the cell source from which stem cells are obtained, the global stem cell therapy market issegmented into four sources. These include adipose tissue-derived MSCs (mesenchymal stem cells), bone marrow-derived MSCs, placenta/umbilical cord-derived MSCs, and other cell sources (which include human corneal epithelium stem cells, peripheral arterial-derived stem cells, and induced pluripotent stem cell lines). The bone marrow-derived MSCs segment is expected to witness the highest growth rate during the forecast period, owing to an increasing number of clinical trials focused on bone marrow-derived cell therapies and the rising demand for these cells in blood-related disorders.

Asia Pacific: The fastest-growing countryin thestem cell therapy marketThestem cell therapy market is segmented into North America, Europe, Asia Pacific,RoW.The stem cell therapy market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period.

Factors such as the growing adoption of stem cell-based treatment in the region and the growing approval & commercialization of stem cell-based products for degenerative disorders drive the growth of the stem cell therapy market in the region.

The primary interviews conducted for this report can be categorized as follows: By Respondent: Supply Side- 80%and Demand Side 20% By Designation: C-level - 25%, D-level - 20%, and Others - 55% By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10%

Lists of Companies Profiled in the Report: Smith & Nephew (UK) MEDIPOST (South Korea) Anterogen (South Korea) CORESTEM (South Korea) PHARMICELL (South Korea) NuVasive (US) RTI Surgical (US) AlloSource (US) JCR Pharmaceuticals (Japan) Takeda Pharmaceutical Company (Japan) HolostemTerapieAvanzateS.r.l (Italy) Orthofix (US) Regrow Biosciences (India) Stempeutics Research (India) Athersys (US), Mesoblast (Australia), BioRestorative Therapies (US) Pluristem Therapeutics (Israel) BrainStorm Cell Therapeutics (US) ViaCyte (US) Kangstem Biotech (South Korea) Hope Biosciences (US) Cellular Biomedicine Group (US) and Personalized Stem Cells (US)

Research Coverage:This report provides a detailed picture of thestem cell therapy market.It aims at estimating the size and future growth potential of the market across different segments, such as the service, end user, and region.

The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall stem cell therapy marketand its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the markets pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.Read the full report:

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


Story continues

See more here:

The global stem cell therapy market is projected to reach USD 401 million by 2026 from USD 187 million in 2021, at a CAGR of 16.5% - Yahoo Finance

Read more
Diabetes and muscle weakness: Why the link? – Medical News Today

More than 34 million people in the United States have diabetes, and 9095% of these cases are type 2 diabetes.

The cells of people with diabetes are less responsive to insulin, which is the hormone that allows tissues throughout the body to take up glucose from the bloodstream.

One symptom that indicates that a person may be in the early stages of type 2 diabetes is reduced grip strength. Conversely, there is also some evidence to suggest that resistance exercise can lower the risk of developing the condition.

A new study led by scientists at Lund University in Malm, Sweden, helps explain why skeletal muscle weakens in people with type 2 diabetes.

Normally, exercise or injury activates immature cells in muscle tissue, called muscle stem cells. The cells then proliferate and transform into mature muscle fibers in a process known as myogenesis, which regenerates the muscle.

The new research suggests that one of the reasons that muscle tissue does not regenerate properly in people with diabetes is that it does not produce enough of a key protein.

The protein, called VPS39, is part of the molecular machinery that cells use to dispose of damaged components in order to regenerate themselves.

The technical term for this waste disposal system is autophagy, which literally means self-eating.

According to the new research, the gene that makes VPS39 is less active in the muscle cells of people with type 2 diabetes. This impairs the ability of the muscle tissue to generate new muscle fibers and reduces its uptake of glucose.

The gene is important when muscle cells absorb sugar from blood and build new muscle, explains study leader Prof. Charlotte Ling, a professor of epigenetics at Lund University.

Our study is the first ever to link this gene to type 2 diabetes, she adds.

The results of the study appear in the journal Nature Communications.

Prof. Ling and colleagues study epigenetics, which is the way in which genes are switched on and off (or silenced) during the course of a cells development.

Epigenetic changes might result from external and environmental factors or be a consequence of the normal development of cells. Illness and lifestyle factors such as exercise and diet can also cause epigenetic changes in muscle and other tissues.

In people with type 2 diabetes, the condition appears to cause epigenetic changes that silence the VPS39 gene, preventing it from producing the protein of the same name.

The researchers made their discovery by comparing muscle biopsies from 14 people with type 2 diabetes and 14 healthy controls. The team matched the participants for their age, sex, and body mass index (BMI).

When the scientists grew muscle stem cells and mature cells from the volunteers under identical conditions in the laboratory, the activity of 20 genes consistently differed between the two groups.

This suggests that diabetes had caused epigenetic changes in these genes, altering their expression.

Among the genes that differed between the people with type 2 diabetes and the controls was VPS39, which is known to be part of the cellular machinery that controls autophagy.

To investigate the role of VPS39 in muscle regeneration, the researchers silenced the gene in healthy human muscle stem cells.

When the cells could no longer make the VPS39 protein, this triggered a range of changes that closely resembled the changes in muscle stem cells from people with type 2 diabetes.

The net effect was to prevent the cells from developing into mature muscle cells.

[M]uscle stem cells that lack VPS39 due to altered epigenetic mechanisms cannot change their metabolism in the same way as muscle stem cells from controls the cells therefore remain immature or break down and die, says study co-author Johanna Sll Sernevi, a postdoctoral researcher at Lund University.

The researchers further tested this idea by studying genetically modified mice that were deficient in the protein. This mimics the epigenetic change that occurs in people with type 2 diabetes.

Sure enough, there were similar changes in the animals muscle tissue, including reduced uptake of glucose, and changes in the regulation of autophagy and the maturation of muscle cells.

The study authors are optimistic that their discovery could inspire new kinds of treatment for type 2 diabetes.

Such treatment could probably improve both glucose uptake in muscle cells and regeneration of muscle through better ability for muscle stem cells to differentiate into mature muscle fibers, Prof. Ling told Medical News Today.

Our next step is to study the impact of non-genetic risk factors for type 2 diabetes on epigenetics in muscle stem cells, she added. These could include the influence of lifestyle factors such as diet and exercise.

In their paper, the researchers emphasize that they found differences between people with type 2 diabetes and healthy controls in the expression of several genes in addition to VPS39.

Although they focused on the role of VPS39 in this study, they do acknowledge that other genes also contribute to muscle dysfunction and insulin resistance in type 2 diabetes.

See the rest here:

Diabetes and muscle weakness: Why the link? - Medical News Today

Read more
A Peek At The Hand Of Cell, Gene And RNA Therapies – In Vivo

Why do I have to complete a CAPTCHA?

Completing the CAPTCHA proves you are a human and gives you temporary access to the web property.

If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware.

If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices.

Another way to prevent getting this page in the future is to use Privacy Pass. You may need to download version 2.0 now from the Firefox Add-ons Store.

See the rest here:

A Peek At The Hand Of Cell, Gene And RNA Therapies - In Vivo

Read more
Jasper Therapeutics and Amplit –

Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Amplitude Healthcare Acquisition Corporation (Nasdaq: AMHCU), a special purpose acquisition company (SPAC) sponsored by affiliates of Avego Management, LLC and Metalmark Capital, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, anticipated to occur in the third quarter 2021, the combined company will be renamed Jasper Therapeutics, Inc., and its common stock is expected to be listed on Nasdaq under the ticker symbol JSPR.

We would like to thank our financial partners at Amplitude and our prestigious group of investors, said Bill Lis, executive chairman and CEO, Jasper Therapeutics. This transaction provides significant capital to accelerate the development of our two innovative programs, Jaspers first-in-class clinical stage anti-CD117 antibody transplant conditioning agent and in parallel our groundbreaking research stage Engineered Hematopoietic Stem Cell platform, both of which have the potential to transform the field and expand hematopoietic stem cell therapy cures to a far greater number of patients than is possible today.

At Jasper we are focused on a mission to cure several life threatening diseases such as blood cancers, sickle cell disease, severe combined immunodeficiency, and severe autoimmune diseases that affect a large number of patients who have historically been underserved by industry research and development, including infants, women, minorities and the elderly.

In addition to the funds held in Amplitudes trust account (approximately $100 million less any redemptions), the transaction also includes commitments for a $100 million private investment in public equity (PIPE) priced at $10.00 per share. Investors in the PIPE include lead investor Federated Hermes Kaufmann Funds and affiliates of the SPAC sponsor including Avego, Velan Capital and Metalmark, as well as Amgen, Christian Angermayers Apeiron Investment Group, Kingdon Capital Management, and Woodline Partners LP, in addition to existing Jasper investors Abingworth LLP, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Roche Venture Fund and Alexandria Venture Investments, LLC. Jasper Therapeutics is expected to have cash resources of approximately $180 million at the closing of the transaction (less any redemptions from the Amplitude trust account).

The boards of directors of both Jasper Therapeutics and Amplitude have unanimously approved the proposed transaction. Completion of the transaction, which is expected in the third quarter of 2021, is subject to approval of Amplitudes stockholders and the satisfaction or waiver of certain other customary closing conditions.

Jasper Therapeutics has a strong management team with deep scientific expertise in the field and a track record developing and commercializing novel drugs, along with a pipeline that could make it a formidable leader in hematopoietic stem cell transplantation for a broad range of indications, said Vishal Kapoor, President of Amplitude. When Jasper Therapeutics emerges as a public company, it will be positioned as a well-funded leader in hematopoietic stem cell conditioning and engineering, an area that has seen far too little innovation.

Jasper Therapeutics expects to use the cash resources of the combined company following the merger and PIPE to support the clinical development of JSP191, a first-in-class humanized monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for acute myeloid leukemia (AML)/ myelodysplastic syndromes (MDS) and severe combined immunodeficiency (SCID) and is scheduled to begin enrollment in 3 additional studies in 2021 for severe autoimmune disease, sickle cell disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

Jasper Therapeutics also expects to use the cash resources of the combined company to continue to advance its preclinical Engineered Hematopoietic Stem Cell (eHSCs) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. By using mRNA or DNA editing, Jasper Therapeutics can give the donor or gene-edited stem cells a proliferative and survival advantage over the patients existing stem cells. Preclinical data have demonstrated that Jaspers eHSCs grow faster and outcompete normal hematopoietic stem cells and that they can be engineered to become resistant to inhibition by JSP191, suggesting that they could be combinable as a conditioning and therapeutic pair.

Transaction Overview

Assuming a share price of $10.00 per share and no redemptions of Amplitude shares, Jasper Therapeutics is expected to have an initial market capitalization of approximately $490 million dollars. Upon the closing of the business combination, and assuming no redemptions of shares of Amplitude by its public stockholders, Jasper Therapeutics is expected to have cash resources of approximately $180 million at the closing of the transaction (less any redemptions). The proceeds will be funded through a combination of approximately $100 million cash in trust by Amplitude (less any redemptions from its trust account) and a $100 million concurrent PIPE of common stock issued at $10.00 per share, anchored by leading institutional investors. As part of the transaction, Jasper Therapeutics existing equity holders will roll 100% of their equity into the combined company.

The boards of directors of both Jasper Therapeutics and Amplitude have unanimously approved the proposed transaction, which is expected to be completed in the third quarter of 2021. The transaction is subject to, among other things, the approval of the stockholders of both Jasper Therapeutics and Amplitude, satisfaction or waiver of the conditions stated in the definitive business combination agreement.

Additional information about the transaction will be provided in a Current Report on Form 8-K to be filed by Amplitude with the SEC and will be available at the SECs website at In addition, Amplitude intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus, and will file other documents regarding the proposed transaction with the SEC.


Credit Suisse is acting as lead PIPE placement agent and capital markets advisor to Jasper Therapeutics, William Blair is acting as co-placement agent and financial advisor and Cantor Fitzgerald as co-placement agent. Paul Hastings LLP is serving as legal counsel to Jasper Therapeutics. BMO Capital Markets and Oppenheimer & Co. Inc. are acting as capital markets advisors to Amplitude. Wilmer Cutler Pickering Hale and Dorr LLP is serving as legal counsel to Amplitude.


The management team of Jasper Therapeutics will host a webcast on Friday, May 7 at 10:00 am ET to provide a brief overview of Jasper and the proposed merger. The webcast can be accessed here:

About Jasper Therapeutics

Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The companys lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. This first-in-class conditioning antibody is designed to enable safer and more effective curative hematopoietic cell transplants and gene therapies. Jasper Therapeutics is also advancing the development of a novel hematopoietic stem cell engineering platform.

About Amplitude Healthcare Acquisition Corporation

Amplitude was founded by Avego and Metalmark to seek innovative private life sciences company acquisition targets. We leverage our management and boards reputation, experience, and track record of making investments and creating value in the industry. We have a strong history of building and growing companies as constructive and trustworthy partners. For more information, please visit:

Important Information and Where to Find It

This press release relates to a proposed transaction between Jasper Therapeutics and Amplitude. This press release does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. In connection with the transaction described herein, Amplitude intends to file relevant materials with the SEC, including a registration statement on Form S-4, which will include a proxy statement/prospectus. Promptly after the registration statement is declared effective by the SEC, Amplitude will mail the definitive proxy statement/prospectus and a proxy card to each stockholder as of a record date for the meeting of Amplitude stockholders to be established for voting on the proposed business combination. Investors and security holders of Amplitude are urged to read these materials (including any amendments or supplements thereto) and any other relevant documents in connection with the transaction that Amplitude will file with the SEC when they become available because they will contain important information about Amplitude, Jasper Therapeutics and the transaction. The preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other relevant materials in connection with the transaction (when they become available), and any other documents filed by Amplitude with the SEC, may be obtained free of charge at the SECs website ( The documents filed by Amplitude with the SEC also may be obtained free of charge upon written request to 1177 Avenue of the Americas, Fl 40, New York, New York 10036.

Participants in the Solicitation

Amplitude and its directors and executive officers may be deemed participants in the solicitation of proxies from Amplitudes stockholders with respect to the business combination. Information about Amplitudes directors and executive officers and a description of their interests in Amplitude will be included in the proxy statement/prospectus for the proposed transaction and be available at the SECs website ( Additional information regarding the interests of such participants will be contained in the proxy statement/prospectus for the proposed transaction when available.

Jasper Therapeutics and its directors and executive officers may also be deemed to be participants in the solicitation of proxies from the stockholders of Amplitude in connection with the proposed business combination. Information about Jasper Therapeutics directors and executive officers and information regarding their interests in the proposed transaction will be included in the proxy statement/prospectus for the proposed transaction.


This press release is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of Amplitude, the combined company or Jasper Therapeutics, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act of 1933, as amended.

Special Note Regarding Forward-Looking Statements

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the proposed business combination between Amplitude and Jasper Therapeutics, the estimated or anticipated future results and benefits of the combined company following the business combination, including the likelihood and ability of the parties to successfully consummate the business combination, future opportunities for the combined company, the timing of the completion of the proposed business combination, Jasper Therapeutics business strategy, expected cash resources of the combined company and the expected uses thereof, current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the respective management teams of Jasper Therapeutics and Amplitude and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper Therapeutics and Amplitude. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the inability of the parties to consummate the transactions or the occurrence of any event, change or other circumstances that could give rise to the termination of the business combination agreement; the failure to satisfy the minimum cash condition set forth in the business combination agreement, whether due to redemptions from the Companys trust account or otherwise; the failure of the PIPE financing to close on the terms and in the amounts currently anticipated; the outcome of any legal proceedings that may be instituted against the parties following the announcement of the Business Combination; the risk that the potential product candidates that Jasper Therapeutics develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jasper Therapeutics product candidates; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper Therapeutics will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jasper Therapeutics product candidates may not be beneficial to patients or successfully commercialized; the risk that Jasper Therapeutics has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper Therapeutics business; the risk that third parties on which Jasper Therapeutics depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper Therapeutics business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper Therapeutics will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; the potential inability of the parties to successfully or timely consummate the proposed transaction, including the risk that any requisite regulatory approvals to complete the transaction are not obtained, are delayed or are subject to unanticipated conditions that could adversely affect the combined company or the expected benefits of the proposed transaction or that the approval of the stockholders of Amplitude or Jasper Therapeutics is not obtained; the risk of failure to realize the anticipated benefits of the proposed transaction; the amount of redemption requests made by Amplitudes stockholders and other risks and uncertainties indicated from time to time in the Amplitudes public filings, including its most recent Annual Report on Form 10-K for the year ended December 31, 2020 and the proxy statement/prospectus relating to the proposed transaction, including those under Risk Factors therein, and in Amplitudes other filings with the SEC. If any of these risks materialize or Amplitudes and Jasper Therapeutics assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither Amplitude nor Jasper Therapeutics presently know, or that Amplitude or Jasper Therapeutics currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Amplitudes and Jasper Therapeutics expectations, plans or forecasts of future events and views as of the date of this press release. Amplitude and Jasper Therapeutics anticipate that subsequent events and developments will cause Amplitudes and Jasper Therapeutics assessments to change. However, while Amplitude and Jasper Therapeutics may elect to update these forward-looking statements at some point in the future, Amplitude and Jasper Therapeutics specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing Amplitudes and Jasper Therapeutics assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

This press release contains certain financial forecast information of Jasper Therapeutics. Such financial forecast information constitutes forward-looking information, and is for illustrative purposes only and should not be relied upon as necessarily being indicative of future results. The assumptions and estimates underlying such financial forecast information are inherently uncertain and are subject to a wide variety of significant business, economic, competitive and other risks and uncertainties. See "Special Note Regarding Forward-Looking Statements" above. Actual results may differ materially from the results contemplated by the financial forecast information contained in this press release, and the inclusion of such information in this press release should not be regarded as a representation by any person that the results reflected in such forecasts will be achieved.

View source version on

Read this article:

Jasper Therapeutics and Amplit -

Read more
The Stem Cell Chronicles: Dr. Beau Hightower On Incredible Health Benefits of SCT – Maxim


Presented by BioXcellerator

We recently shined a light on stem cell therapy (SCT) and its great potential with wellness, health, recovery and at-times life-changing treatments.Our focus centered on the esteemed BioXcellerator clinic in Medelln, Colombia, and how their treatments can extend longevity, boost immunity and enhance overall quality of life while reducing the impact of aging.

To further this message, we will speak with real-life patients of BioXcellerator who have taken their treatments and experienced first-hand the efficacy of this promising future medicine.

First up we have Dr. Beau Hightower, super chiropractic physician to countless athletes, UFC fighters and professional wrestlers and of course regular folk as well at his ELITE-OSM ortho-therapy clinicsin New Mexico and Nevada.

A Naprapath Doctor, Certified Exercise Physiologist, Certified Strength and Conditioning Specialist and Master of Science, Dr. Hightower commands a huge YouTube following (almost 3 million subscribers) and dedicated fans who have benefitted greatly from the doctor's sage advice.

His wife Lais DeLeon Hightower Brazilian model, trainer and wellness celebrity with a massive following of her own joins Dr. Beau in his Testimonial. Beyond the video below, the good doctor shares a bit of background on his time at BioXcellerator.

How did you hear about BioXcellerator, and was it personally recommended?

I heard about BioXcellerator from several athletes that I treat, particularly UFC fighters and wrestlers. The person who told me the most about it however was [two-time UFC Welterweight Champion/UFC Hall of Fame inductee] Matt Hughes who personally recommended BioXcellerator.

Had you heard of Stem Cell Therapy before hearing about BioXcellerator, or vice versa? Its a big decision how did you advance from simply mulling it over to pressing the trigger and flying to Colombia?

Yes I was very aware of stem cell therapy and I've been keeping a close eye on it for over a decade in practice. I've had several patients get bone marrow and fat variations of stem cell therapy here in the United States, but I was always under the impression that Umbilical cord/Wharton jelly stem cell therapy which BioXcellerator uses are the more superior cells.

I began researching the efficacy of stem cell therapy for a few ailments that I have been dealing with and I found some compelling evidence in the literature. After speaking with BioXcellerator and studying the literature, I realized it was time for me to take the first step in trying to make my life better. I also realize that before I can make the recommendation for my patients to receive stem cells from BioXcellerator that I would need to go through the process first to know for sure what the outcomes were.

What did you think of the professionalism and care of BioXcellerator while at their clinic?

The communication with BioXcellerator was top-notch. The concierge staff made us feel perfectly at home in Medelln, made us feel very safe and their facilities are incredibly clean and high-tech. I actually had an opportunity to speak with a medical director and scientists who demonstrated the exact way they extract and grow their stem cells and was beyond impressed.

What did you think of Colombia? Were you concerned about anything (e.g. safety, not speaking the language, etc), and how did it go?

I love Colombia the food is fantastic, the people are friendly, and the cultures incredibly rich. The weather in Medelln was outstanding as they call it the City of Eternal Spring. I've actually lived in Columbia prior to this in Bogota so I was very familiar with Colombian culture. We had a great experience and we really enjoyed the local restaurants and particularly the hotel and the mall that connects to the medical facility. It was an outstanding wellness vacation and I can't recommend it nearly enough.

What were the most powerful effects you felt after your treatments?

My intestines have healed about 80% since my trip to Columbia, my knee pain has decreased by about 70% since my trip and doesn't crack or pop anymore. My hip pain has decreased drastically as well, and my shoulder is significantly more stable which helps me to do my job taking care of elite UFC athletes. All In all, I was very skeptical but BioXcellerator has exceeded my wildest expectations by 1,000 fold.

Read the original here:

The Stem Cell Chronicles: Dr. Beau Hightower On Incredible Health Benefits of SCT - Maxim

Read more
HealthLynked Releases Recent "Future of Healthcare" Summit in Virtual Format – PRNewswire

NAPLES, Florida, May 6, 2021 /PRNewswire/ --HealthLynked(OTCQB: HLYK) a global healthcare network focused on care management of its members and a provider of healthcare technologies that connects doctors, patients, and medical data, today announced the release of their recent "Future of Healthcare" summit in a virtual format The event, held at the Arthrex Campus in Naples, Florida, from March 15-17th, brought thought leaders from around the world to Naples for a three-day event focusing on emerging healthcare technologies. The virtual summit featured twenty-nine lectures from leading experts in their fields covering: stem cells, regenerative medicine, anti-aging, cancer diagnosis, artificial intelligence, and advanced DNA testing. HealthLynked's dedication to improving healthcare recognizes that the education of patients and healthcare providers is an important part of their mission and their HealthLynked University website currently hosts over 100 educational videos on a wide range of medical topics.

Due to COVID-19 and the limited seating for the event, the virtual summit was created to meet the request of people that were unable to attend the event to view the content. The virtual event is separated into 7 key topics: Stem cells, Genomics, Cancer, Healthcare Technology, Lifestyle Therapies, The Future of Healthcare, and The Future Talks.

Featured Speakers and Topics:

All twenty-nine lectures can be viewed by going to Registration for the virtual summit is only $49.99.

Dr. Michael Dent, CEO of HealthLynked stated, "The Future of Healthcare Summit was a huge success and the feedback we have received on the lectures and content has been exceptional. We have had many requests for the content to be made available by healthcare providers and others who were unable to attend due to COVID. The Virtual Summit was created to make the event available to a much larger audience. We plan to continue hosting the event in Naples on an annual basis and expect an even larger audience in 2022."

About HealthLynked Corp.

HealthLynked Corp. provides a solution for both patient members and providers to improve healthcare through the efficient exchange of medical information. The HealthLynked Network is a cloud-based platform that allows members to connect with their healthcare providers and take more control of their healthcare. Members enter their medical information, including medications, allergies, past surgeries, and personal health records, in one convenient online and secure location, free of charge. Participating healthcare providers can connect with their current and future patients through the system. Benefits to in-network providers include the ability to utilize the HealthLynked patent-pending patient access hub "PAH" for patient analytics. Other benefits for preferred providers include HLYK marketing tools to connect with their active and inactive patients to improve patient retention, access more accurate and current patient information, provide more efficient online scheduling, and to fill last-minute cancelations using the Company's "real-time appointment scheduling" all within its mobile application. Preferred providers pay a monthly fee to access these HealthLynked services. For additional information about HealthLynked Corp., please visit and connect with HealthLynked on Twitter, Facebook, and LinkedIn.

Forward-Looking Statements

Forward-Looking Statements in this press release, which are not historical facts, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our actual results, including as a result of any acquisitions, performance, or achievements may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by our management, and us are inherently uncertain. We caution you not to place undue reliance on any forward-looking statements, which are made as of the date of this press release. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. Certain risks and uncertainties applicable to our operations and us are described in the "Risk Factors" section of our most recent Annual Report on Form 10-K and in other filings we have made with the U.S. Securities and Exchange Commission. These reports are publicly available at


George O'LearyChief Financial Officer[emailprotected] (800)-928-7144, ext. 103

William HaydeCapital Markets Strategist[emailprotected] (631)-403-4337

Investor Relations Contacts:Jim HockHanover International Inc.[emailprotected] (760)-564-7400

SOURCE HealthLynked Corp.

See original here:

HealthLynked Releases Recent "Future of Healthcare" Summit in Virtual Format - PRNewswire

Read more
Kill Cancer with Fasting – Greater Kashmir

Fastingis the willful refraining from eating and drinking. In a physiological context, fastingmay be referred to the metabolic status of a person who has not eaten overnight, or to the metabolic state achieved after complete digestion and absorption of a meal. Several metabolic adjustments occur during fasting. Some diagnostic tests are used to determine a fasting state. For example, a person is assumed to be fasting once 812 hours have elapsed since the last meal. Metabolic changes of the fasting state begin after absorption of a meal. Fasting refers to not eating at all or consuming very fewcaloriesfor a certain amount of time. And fasting from12 hourstoprolonged periods have promising results in cancer treatment and prevention,

Fastingis one of the oldest therapies in medicine. Many renowned physicians throughout history and many of the oldest healing systems have recommended fasting as an integral method of healing and prevention.Buqrat(Hippocrates), Father of Unani or Greek Medicine,believed that fasting enabled the body to heal itself.

Fastingtriggers a truly wondrous cleaning process that trickles down to each cell in the body, a highly potent natural anti-inflammatory therapy; it releases cooling energy throughout the system. Fasting is a good way to detoxify, thereby cleansing the body system of ill-effects including cancer.There is a great relation between calorie restriction,fasting and prevention of cancer in the body.

FastingHelp Fight Cancer?

According to Medical Science, fasting may help with cancer treatment. There is a growing body of evidence supporting the role of fasting in both cancer treatment and prevention. Some research suggests that fasting helps fightcancerby loweringinsulin resistanceand levels ofinflammation. Fasting may also reverse the effects of chronic conditions such asobesityandtype 2 diabetes, which are both linked to a higher risk of multiple types of cancer and lower survival rates. Inone studyof time-restricted feeding during 912 hour phases, fasting was shown to reverse the progression of obesity andtype 2 diabetesin mice.Obesityis a major risk factor for cancer, which may support fasting to treat cancer.

Also, researchers believe that fasting may make cancer cells more responsive tochemotherapywhile protecting other cells. Fasting may also boost the immune system to help fight cancer that is already present. Over the past several years, many studies have been published showing thatintermittent fastingor a fasting-mimicking diet can reduce risk factors for and reverse symptoms of serious health conditions includingcancer.

According to Japanese Biologist Ishinori Osimi who won the Nobel Prize in 2016 in Medicine for his research study on fastingclaims that fastingfor 12 to 24 hours can start autophagy in the human body. He proves in his study the benefits claimed by various people through fasting e.g., body cells are cleansed, cancer cells are destroyed, cure in inflammatory conditions of stomach, increase in brain functionality, self-healing of body (autophagy), cure in diabetes, prevention and delayed-aging, reduction in obesity, and longevity of life, etc, etc,

He further says that fastingfor 20 to 25 days for 9 to 10 hours in a year helps the human body get cleansed from cancer cells.

As Will of Allah, the fasting in the pious month of Ramdaan would do much more to treat cancer, than the scientific studies predict and infer.

FastingPromotes Autophagy

One of the benefits of fasting is autophagy, which causes cellular cleanup and recycling of defective organelles like the mitochondria. Autophagy is a cellular process in which parts of cells break down for later reuse. Autophagy is critical for maintaining proper cell function, and it also helps defend cells in the body. Autophagy plays an important role in preventing and treating cancer. Severalstudiesin mice suggest that autophagy may prevent cancer. Some researchers believe that fasting improves peoples response to chemotherapy because it promotes cellular regeneration, protects blood against the harmful effects of chemotherapy and reduces the impact of side effects, such asfatigue, nausea,headaches, and cramps.

Science Behind Fasting and Cancer

Weight loss is just onebenefit of intermittent fastingfor a normal healthy (disease-free) adult. Recent animal studies and a few preliminary human trials have shown a decrease in risk for cancer or a decrease in cancer growth rates. These studies indicate this may be due to the effects from fasting that cause decreased blood glucose production, triggering of stem cells to regenerate the immune system, balanced nutritional intake, and an increased production of tumor-killing cells. In a study on mice showed that a bimonthly fasting-mimicking diet reduced the incidence of cancer. Results were similar in a pilot trial by the same scientists with 19 humans; it showed decreasedbiomarkersand risk factors for cancer.

In a2016 study, research showed that a combination of fasting and chemotherapy slowed the progression ofbreast cancerandskin cancer. The same study noted short-term starvation makes cancer cells sensitive to chemotherapy while protecting normal cells, and it also promoted the production ofstem cells.

This entire monthly process during Ramadan, detoxify or detoxicate his / her whole body ofmadda-e-faasidah(ill-effects or morbid matters or disease matters) thus cleaning the body of or morbid matters including cancer cells (referred here as free radicals), a Concept of Istifragh in Unani Medical Science in vogue since Centuries, which may ultimately lead to development of cancer, because it is said that the free radicals are responsible for the development of cancer, since the damage to cells caused by free radicals, especially damage to DNA, may play a role in the development of cancer and other health conditions.

FastingImproves Insulin Sensitivity

Fastingalso helps improve the effectiveness of chemotherapy and better insulin sensitivity makes it harder for cancer cells to grow or develop.A2018 studyfound that fasting can improve quality of life in people undergoing chemotherapy forbreast cancerorovarian cancer. The study used a 60-hour fastingperiod starting 36 hours before the start of chemotherapy treatment. The results show that participants fasting during chemotherapy reported higher tolerance to chemotherapy, fewer chemotherapy-related side effects, and higher energy levels when compared with those who did not fast.

Boosting the Immune System to Fight Cancer

A2014 studyexamined whether fasting produces any cancer-fighting effects in micestem cells. Stem cells are important due to their regenerative abilities. The researchers revealed thatfastingfor 24 days may protect stem cells against the negative effects of chemotherapy on the immune system.Fastingalso activates stem cells of the immune system to renew and repair themselves. This study shows thatfastingnot only reduces damage to cells, it also replenishes white blood cells and replaces damaged ones. White blood cells fight infection and destroy cells that may cause disease. When white blood cell levels drop as a result of chemotherapy, it affects the immune system negatively. This means that the body has a harder time fighting infections.The number of white blood cells in the body decreases duringfasting.We all have lots of cancer cells in our bodies at any given time, and our immune system kills many of them.


Now, when fasting for 24 days may protect stem cells against the negative effects of chemotherapy on the immune system and when it also activates stem cells of the immune system to renew and repair themselves, then one can think the level of benefits that would be achieved by fasting for 29 to 30 days during Ramdaan and thereby increasing the level of renewal and repair of immune system which ultimatelyhelp prevent and control the development of cancer in the body.

Thus, Allah knows what is beneficial for a human being, so, He does and commands for.And with great confidence and faith, it can be explicitly inferred that the Fasting schedule prescribed in Ramdaan is the best Medical Protocol and produces the best results by cleansing the body and destroys cancer cells, cures inflammatory conditions of stomach, increase in brain functionality, self-healing of body (autophagy), diabetic cure, prevention and delayed-aging, reduction in obesity, and longevity of life and much more.

The author is ex-Deputy Director (Unani),& Professor ofMoalajat(Clinical Medicine), Ministry of AYUSH, Srinagar.

Read more:

Kill Cancer with Fasting - Greater Kashmir

Read more
Are labgrown embryos and human hybrids ethical? – Big Think

In Aldous Huxley's 1932 novel Brave New World," people aren't born from a mother's womb. Instead, embryos are grown in artificial wombs until they are brought into the world, a process called ectogenesis.

In the novel, technicians in charge of the hatcheries manipulate the nutrients they give the fetuses to make the newborns fit the desires of society. Two recent scientific developments suggest that Huxley's imagined world of functionally manufactured people is no longer far-fetched.

On March 17, 2021, an Israeli team announced that it had grown mouse embryos for 11 days about half of the gestation period in artificial wombs that were essentially bottles. Until this experiment, no one had grown a mammal embryo outside a womb this far into pregnancy. Then, on April 15, 2021, a U.S. and Chinese team announced that it had successfully grown, for the first time, embryos that included both human and monkey cells in plates to a stage where organs began to form.

As both a philosopher and a biologist I cannot help but ask how far researchers should take this work. While creating chimeras the name for creatures that are a mix of organisms might seem like the more ethically fraught of these two advances, ethicists think the medical benefits far outweigh the ethical risks. However, ectogenesis could have far-reaching impacts on individuals and society, and the prospect of babies grown in a lab has not been put under nearly the same scrutiny as chimeras.

Mouse embryos were grown in an artificial womb for 11 days, and organs had begun to develop.

When in vitro fertilization first emerged in the late 1970s, the press called IVF embryos test-tube babies," though they are nothing of the sort. These embryos are implanted into the uterus within a day or two after doctors fertilize an egg in a petri dish.

Before the Israeli experiment, researchers had not been able to grow mouse embryos outside the womb for more than four days providing the embryos with enough oxygen had been too hard. The team spent seven years creating a system of slowly spinning glass bottles and controlled atmospheric pressure that simulates the placenta and provides oxygen.

This development is a major step toward ectogenesis, and scientists expect that it will be possible to extend mouse development further, possibly to full term outside the womb. This will likely require new techniques, but at this point it is a problem of scale being able to accommodate a larger fetus. This appears to be a simpler challenge to overcome than figuring out something totally new like supporting organ formation.

The Israeli team plans to deploy its techniques on human embryos. Since mice and humans have similar developmental processes, it is likely that the team will succeed in growing human embryos in artificial wombs.

To do so, though, members of the team need permission from their ethics board.

CRISPR a technology that can cut and paste genes already allows scientists to manipulate an embryo's genes after fertilization. Once fetuses can be grown outside the womb, as in Huxley's world, researchers will also be able to modify their growing environments to further influence what physical and behavioral qualities these parentless babies exhibit. Science still has a way to go before fetus development and births outside of a uterus become a reality, but researchers are getting closer. The question now is how far humanity should go down this path.

Chimeras evoke images of mythological creatures of multiple species like this 15th-century drawing of a griffin but the medical reality is much more sober. (Martin Schongauer/WikimediaCommons)

Humanmonkey hybrids might seem to be a much scarier prospect than babies born from artificial wombs. But in fact, the recent research is more a step toward an important medical development than an ethical minefield.

If scientists can grow human cells in monkeys or other animals, it should be possible to grow human organs too. This would solve the problem of organ shortages around the world for people needing transplants.

But keeping human cells alive in the embryos of other animals for any length of time has proved to be extremely difficult. In the human-monkey chimera experiment, a team of researchers implanted 25 human stem cells into embryos of crab-eating macaques a type of monkey. The researchers then grew these embryos for 20 days in petri dishes.

After 15 days, the human stem cells had disappeared from most of the embryos. But at the end of the 20-day experiment, three embryos still contained human cells that had grown as part of the region of the embryo where they were embedded. For scientists, the challenge now is to figure out how to maintain human cells in chimeric embryos for longer.

Some ethicists have begun to worry that researchers are rushing into a future of chimeras without adequate preparation. Their main concern is the ethical status of chimeras that contain human and nonhuman cells especially if the human cells integrate into sensitive regions such as a monkey's brain. What rights would such creatures have?

However, there seems to be an emerging consensus that the potential medical benefits justify a step-by-step extension of this research. Many ethicists are urging public discussion of appropriate regulation to determine how close to viability these embryos should be grown. One proposed solution is to limit growth of these embryos to the first trimester of pregnancy. Given that researchers don't plan to grow these embryos beyond the stage when they can harvest rudimentary organs, I don't believe chimeras are ethically problematic compared with the true testtube babies of Huxley's world.

Few ethicists have broached the problems posed by the ability to use ectogenesis to engineer human beings to fit societal desires. Researchers have yet to conduct experiments on human ectogenesis, and for now, scientists lack the techniques to bring the embryos to full term. However, without regulation, I believe researchers are likely to try these techniques on human embryos just as the now-infamous He Jiankui used CRISPR to edit human babies without properly assessing safety and desirability. Technologically, it is a matter of time before mammal embryos can be brought to term outside the body.

While people may be uncomfortable with ectogenesis today, this discomfort could pass into familiarity as happened with IVF. But scientists and regulators would do well to reflect on the wisdom of permitting a process that could allow someone to engineer human beings without parents. As critics have warned in the context of CRISPR-based genetic enhancement, pressure to change future generations to meet societal desires will be unavoidable and dangerous, regardless of whether that pressure comes from an authoritative state or cultural expectations. In Huxley's imagination, hatcheries run by the state grew a large numbers of identical individuals as needed. That would be a very different world from today.

Sahotra Sarkar, Professor of Philosophy and Integrative Biology, The University of Texas at Austin College of Liberal Arts

This article is republished from The Conversation under a Creative Commons license. Read the original article.

From Your Site Articles

Related Articles Around the Web

Go here to read the rest:

Are labgrown embryos and human hybrids ethical? - Big Think

Read more
Stem cell therapy for COPD: Cost, effectiveness, and more – Medical News Today

Currently, the Food and Drug Administration (FDA) has not approved the use of stem cell therapy for the treatment of lung conditions, such as chronic obstructive pulmonary disease (COPD).

The American Lung Association says that this lack of approval is due to the fact that these treatments have high costs, unproven benefits, and the potential to cause harm.

COPD is a progressive, incurable disease that affects at least 16 million people in the United States. As current treatments cannot cure COPD, many people with this condition seek alternative therapies, such as stem cell therapy.

Keep reading to learn more about the potential for using stem cells to treat COPD, including cost, clinical trials, and more.

Stem cells are cells from either embryos or adults that can divide and renew. Although they are not specialized, they can become specialized and ultimately function as cells in various body parts.

Due to their regenerative power and ability to function as different types of cells, stem cells can help repair or replace damaged tissue. Scientists are interested in using stem cell therapy in the treatment of several chronic diseases.

However, most researchers and organizations state that there is not yet enough evidence of the effectiveness of stem cell therapy and knowledge about the long-term risks.

A recent summary of research showed that most human studies have indicated that there is little benefit to the therapy. The author notes that researchers need to understand more about many aspects of stem cell therapy, including:

In other words, more large scale studies must take place to prove or disprove stem cell therapys safety and effectiveness for the majority of people.

The American Lung Association joined many other organizations in signing a statement recommending against stem cell therapy for COPD. The concerns of these groups include:

However, stem cell therapy has shown some potential as a treatment option. According to the American Thoracic Society (ATS), the therapy has shown promise in animal studies. The ATS also notes that sufficient human studies are still lacking, so a person should avoid the therapy unless they are participating in a clinical trial.

The National Emphysema Foundation points out that people who have used unproven stem cell therapies are often willing to get further infusions, suggesting a positive experience.

Finally, the Regeneration Center of Thailand offers and supports the use of stem cell therapy to treat COPD and other lung diseases. However, to receive treatment, a person would need to travel to Thailand, adding to the costs of an already potentially expensive procedure.

As the FDA has not approved stem cell therapy for the treatment of COPD, a person will need to cover all of the costs on their own. They will also need to accept all of the risks associated with using an experimental treatment.

Medicare and private insurance companies will not help cover the costs. A person may not be able to use any healthcare savings account money for the procedure either.

Prices are likely to vary among clinics, very few of which, if any, list the treatment costs upfront. A company called DVC Stem offers stem cell therapy in the Cayman Islands and states that the average cost of treatment is between $10,000 and $35,000. It advises people interested in receiving stem cell therapy to join a clinical trial.

Clinical trials are controlled experiments in which researchers test a new treatment in a group of volunteers. The tests help researchers determine how well the treatment works, the possible side effects, and the ideal dosage, among other factors.

Clinical trials take place in phases, with each phase representing a level of confidence in the treatment. Clinical trials typically go through four phases:

A person interested in joining a stem cell therapy clinical trial should talk with their doctor first. The doctor can help determine whether they will be a good fit for a particular study and may be able to recommend a study based on their condition and health. offers people a way to search for clinical trials related to COPD and stem cell therapy. The listed trials are all approved and regulated for safety. The website lists information about the phase of the trial, who is eligible to participate, and other relevant information.

There is limited knowledge about the short- and long-term side effects of stem cell therapy. In other words, more studies are necessary for researchers to understand precisely how stem cell therapy may affect a person living with COPD.

Alternative or complementary therapies are treatments that fall outside the scope of conventional practice in U.S. medicine. People typically receive these therapies alongside conventional treatment to help support mental health, reduce side effects, and improve quality of life.

The American Thoracic Society states that people can try several alternative or complementary therapies for COPD. These include:

Stem cell therapy for COPD is currently not well-understood. Many researchers and organizations, including the American Lung Association, are concerned about the effectiveness and safety of the therapy.

A person can seek stem cell therapy from unapproved clinics, but the treatment often has high costs with no insurance coverage.

As a result, a better approach is to talk with a doctor about joining a registered clinical trial.

The rest is here:

Stem cell therapy for COPD: Cost, effectiveness, and more - Medical News Today

Read more